Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $75.00 price target on the biotechnology company's stock. HC Wainwright's price target points to a potential downside of 30.52% from the company's previous close.

A number of other equities research analysts have also recently weighed in on SRPT. Piper Sandler lowered their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a report on Wednesday, November 27th. Guggenheim boosted their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. Finally, Jefferies Financial Group started coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $176.77.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $1.51 during midday trading on Thursday, hitting $107.95. The company had a trading volume of 630,697 shares, compared to its average volume of 847,020. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business has a 50-day simple moving average of $119.42 and a two-hundred day simple moving average of $124.60. Sarepta Therapeutics has a twelve month low of $102.15 and a twelve month high of $173.25. The firm has a market capitalization of $10.31 billion, a price-to-earnings ratio of 86.36 and a beta of 0.75.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Capital International Investors boosted its stake in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the period. Norges Bank purchased a new position in Sarepta Therapeutics in the fourth quarter valued at about $126,315,000. Wellington Management Group LLP grew its stake in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth approximately $79,425,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after buying an additional 543,143 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.